AChE/BuChE-IN-1 is a selective butyrylcholinesterase (BuChE) inhibitor with potential for Alzheimer's disease (AD) research; it also inhibits acetylcholinesterase (AChE), exhibits strong hydroxyl radical (·OH) scavenging activity, suppresses reactive oxygen species (ROS) and Aβ1-42 aggregation (including self-, Cu2+-, and AChE-induced aggregation), and demonstrates high blood-brain barrier (BBB) permeability, high bioavailability, and low cytotoxicity.